Not all brands are created equal: A comparison of selected components of different brands of Serenoa repens extract

Prostate Cancer and Prostatic Diseases

Volumn 7, Issue 3, 2004, Pages 195-200

  Habib, F K ^a   Wyllie, M G ^b  

^a WESTERN GENERAL HOSPITAL   (United Kingdom)

^b Urodoc Ltd   (United Kingdom)

Author keywords

Benign prostatic hyperplasia; Free fatty acids; Phytotherapy; Serenoa repens

Indexed keywords

ACYLGLYCEROL; FATTY ACID ESTER; LONG CHAIN FATTY ACID; PROSTA URGENINE; PROSTAGUTT UNO; PROSTAMOL UNO; PROSTEREN; PROSTESS; QUANTERRA PROSTATE; RATIOPHARM UNO; RILAPROST; SABA; SABAL EXTRACT; SITA; SOLARAY; STROGEN UNO; TALSO UNO; TRIACYLGLYCEROL; PLANT EXTRACT;

DRUG DETERMINATION; DRUG DOSAGE FORM; DRUG EFFICACY; DRUG FORMULATION; DRUG LABELING; DRUG SAFETY; HUMAN; PRIORITY JOURNAL; PROSTATE HYPERTROPHY; REVIEW; SABAL; TREATMENT INDICATION; URETHRA DISEASE; CHEMISTRY; MALE; PHYTOTHERAPY; URINARY TRACT INFECTION;

HUMANS; MALE; PHYTOTHERAPY; PLANT EXTRACTS; PROSTATIC HYPERPLASIA; SERENOA; URINARY TRACT INFECTIONS;

EID: 16644375532     PISSN: 13657852     EISSN: 14765608     Source Type: Journal    
DOI: 10.1038/sj.pcan.4500746     Document Type: Review

References (31)

1. Association Européenne des Spécialités Pharmaceutiques Grand Public. (AESPG; 1999) Herbal medicinal products in the European Union. European Commission. http://pharmacos.eudra.org/F2/pharmacos/docs/doc99/ Herbal%20Medecines%20EN.pdf.
2. Lee MR. Plants against malaria, part 2: Artemisia annua (Qinghaosu or the sweet wormwood). J R Coll Physicians Edinb 2002; 32: 300-305.
3. Chiang LC et al. Cytotoxicity and anti-hepatitis B virus activities of saikosaponins from Bupleurum species. Planta Med 2003; 69: 705-709.
4. Arias E. United States life tables, 2000. Natl Vital Stat Rep 2002; 51: 1-38.
5. Gerber GS. Phytotherapy for benign prostatic hyperplasia. Curr Urol Rep 2002; 3: 285-291.
6. Vallancien G, Pariente P. Treatment of lower urinary tract symptoms suggestive of benign prostatic obstruction in real life practice in France. Frost Cancer Prostatic Dis 2001; 4: 124-131.
7. Di Silverio F et al. Plant extracts in benign prostatic hyperplasia. Minerva Urol Nefrol 1993; 45: 143-149.
8. Buck AC. Phytotherapy for the prostate. BJU Int 1996; 78: 325-326.
9. Bales G, Christiano AF, Kirsh E, Gerber GS. Phytotherapeutic agents in the treatment of lower urinary tract symptoms: A demographic analysis of awareness and use at the University of Chicago. Urology 1999; 54: 86-89.
10. Gerber G, Kuznetsov D, Johnson BC, Burstein JD. Randomised, double-blind, placebo-controlled trial of saw palmetto in men with lower urinary tract symptoms. Urology 2002; 58: 960-965.
11. Wilt T, Ishani A, MacDonald R. Serenoa repens for benign prostatic hyperplasia (Cochrane Review). In: The Cochrane Library, Issue 3. Oxford: Update Software, 2002.
12. Aliaev IG, Vinarov AZ, Lokshin KL, Spivak LG. Five-year experience in treating patients with prostatic hyperplasia patients with permixone (Serenoa repens Pierre Fabre Medicament). Urologiia 2002; Jan-Feb 23-25.
13. Bayne CW, Donnelly F, Ross M, Habib FK. Serenoa repens (Permixon®): A 5α-reductase types I and II inhibitor-new evidence in a coculture model of BPH. The Prostate 1999; 40: 232-241.
14. Paubert-Braquet M et al. Effect of the lipido-sterolic extract of Serenoa repens (Permixon®) and its major components on basic fibroblast growth factor-induced proliferation of cultures of human prostate biopsies. Eur Urol 1998; 33: 340-347.
15. Vacherot F et al. Induction of apoptosis and inhibition of cell proliferation by the lipido-sterolic extract of Serenoa repens (LSESr, Permixon®) in benign prostatic hyperplasia. The Prostate 2000; 45: 259-266.
16. Mitropoulos D et al. In vivo effect of the lipido-sterolic extract of Serenoa repens (Permixon®) on mast cell accumulation and glandular epithelium trophism in the rat prostate. World J Urol 2002; 19: 457-461.
17. Weisser H, Tunn S, Behnke B, Krieg M. Effects of the Sabal serrulata extract IDS 89 and its subfractions on 5 alpha-reductase activity in human benign prostatic hyperplasia. The Prostate 1996; 28: 300-306.
18. Raynaud JP, Cousse H, Martin PM. Inhibition of type 1 and type 2 5alpha-reductase activity by free fatty acids, active ingredients of Permixon. J Steroid Biochem Mol Biol 2002; 82: 233-239.
19. 4) from human polymorphonuclear neutrophils. Prostaglandins Leukot Essent Fatty Acids 1997; 57: 299-304.
20. Raso GM et al. Inhibition of inducible nitric oxide synthase and cyclooxygenase-2 expression by flavonoids in macrophage J774A.1. Life Sci 2001; 68: 921-931.
21. Descotes JL, Rambeaud JJ, Deschaseaux F, Faure G. Placebo-controlled evaluation of the efficacy and tolerability of Permixon® in benign prostatic hyperplasia after exclusion of placebo responders. Clin Drug Invest 1995; 9: 291-297.
22. Carraro JC et al. Comparison of phytotherapy (Permixon®) with finasteride in the treatment of benign prostatic hyperplasia: A randomized international study of 1,098 patients. The Prostate 1996; 29: 231-240.
23. Debruyne F et al. Comparison of a phytotherapeutic agent (Permixon) with an α-blocker (tamsulosin) in the treatment of benign prostatic hyperplasia: A 1-year randomized international study. Eur Urol 2002; 41: 497-507.
24. Boyle P, Robertson C, Lowe F, Roehrborn CG. Meta-analysis of clinical trials of Permixon in the treatment of symptomatic benign prostatic hyperplasia. Urology 2000; 55: 533-539.
25. Boyle P, Robertson C, Lowe F, Roehrborn CG. Meta-analysis of Permixon in treatment of symptomatic benign prostatic hyperplasia: An update [abstract]. J Urol 2003; 169 (Supp14): 1297.
26. Khoury S et al. International consultation on urological diseases: A decade of progress. The Prostate 2000; 45: 194-199.
27. Garrard J, Harms S, Eberly LE, Matiak A. Variations in product choices of frequently purchased herbs: Caveat emptor. Arch Intern Med 2003; 163: 2290-2295.
28. Kressman S et al. Influence of pharmaceutical quality on the bioavailability of active components from Gingko biloba preparations. J Pharm Pharmacol 2002; 54: 1507-1514.
29. Di Silverio F et al. Effects of long-term treatment with Serenoa repens (Permixon®) on the concentrations and regional distribution of androgens and epidermal growth factor in benign prostatic hyperplasia. The Prostate 1998; 37: 77-83.
30. Bayne CW, Ross M, Donnelly F, Habib FK. The selectivity and specificity of the actions of the lipido-sterolic extract of Serenoa repens (Permixon®) on the prostate. J Urol 2000; 164: 876-881.
31. Van Coppenolle F et al. Pharmacological effects of the lipido-sterolic extract of Serenoa repens (Permixon®) on rat prostate hyperplasia induced by hyperprolactinemia: Comparison with finasteride. The Prostate 2000; 43: 49-58.